Evidence map›Paper›PMID 42286866›Full record

ArticleGut microbes2026

Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy.

Carmen Correale, Martina Morandi, Antonio Gil-Gomez, Alessandra Silvestri, Andrea Gatti, Daniele Braga, Annalisa Maroli, Caterina Foppa, Stefano De Zanet, Francesca Algieri and 7 more

Abstract read
In one paragraph

Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Carmen CorrealeIRCCS Humanitas Research Hospital, Milan, Italy.
Martina MorandiIRCCS Humanitas Research Hospital, Milan, Italy.
Antonio Gil-GomezInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Alessandra SilvestriIRCCS Humanitas Research Hospital, Milan, Italy.
Andrea GattiIRCCS Humanitas Research Hospital, Milan, Italy.
Daniele BragaIRCCS Humanitas Research Hospital, Milan, Italy.
Annalisa MaroliIRCCS Humanitas Research Hospital, Milan, Italy.
Caterina FoppaIRCCS Humanitas Research Hospital, Milan, Italy.
Stefano De ZanetIRCCS Humanitas Research Hospital, Milan, Italy.
Francesca AlgieriPostbiotica S.r.l., Milan, Italy.
Michela LizierIRCCS Humanitas Research Hospital, Milan, Italy.
Riccardo RossettiIRCCS Humanitas Research Hospital, Milan, Italy.
Sara CarloniIRCCS Humanitas Research Hospital, Milan, Italy.
Giuseppe PennaIRCCS Humanitas Research Hospital, Milan, Italy.
Antonino SpinelliIRCCS Humanitas Research Hospital, Milan, Italy.
Paola BresciaIRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-2388-6820
Maria RescignoIRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-6464-509X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced intestinal mucositis is a frequent and dose-limiting toxicity that compromises cancer treatment outcomes and lacks effective targeted interventions. Here, we investigate the mechanisms by which the nonabsorbable antibiotic rifaximin mitigates chemotherapy-induced intestinal injury, focusing on microbiota-mediated preservation of epithelial barrier integrity. In a murine model of 5-fluorouracil (5-FU)-induced intestinal injury, rifaximin pretreatment reduced mucosal inflammation and tissue damage, preserved epithelial and mucus barrier integrity, and limited systemic endotoxemia. Importantly, rifaximin did not impair the antitumor efficacy of 5-FU in Apc

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsGastrointestinal MicrobiomeIntestinal MucosaMucositisRifaximinAnimalsDisease Models, AnimalFluorouracilHumansIntestinal Barrier FunctionMaleMiceMice, Inbred C57BLAnti-Bacterial AgentsAntineoplastic AgentsFluorouracilRifaximinchemotherapy-induced mucositisgut microbiotaintestinal barrierMuribaculumrifaximin

Identifiers

PMID42286866
PMCPMC13274138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.